Valeant Pharmaceuticals Reports First Quarter 2016 Financial Results

Valeant Pharmaceuticals (VRX): Dermatology Is Losing Money - Jefferies

Jefferies analyst, David Steinberg, cut his PT on Valeant Pharmaceuticals (NYSE: VRX) to meet lowered guidance. Q1 revs exceeded consensus by ~$20M while EPS was $0.09 below consensus though both were within mgts guidance range. With a new CEO in place, VRX not surprisingly significantly... More

Valeant (VRX) PT Cut to $33 at RBC Capital

RBC Capital analyst Douglas Miehm lowered estimate and his price target on Sector Perform-rated Valeant Pharmaceuticals (NYSE: VRX) to $33.00 (from $58.00) following mixed earnings, which were overshadowed by sharply lower guidance.

Miehm commented, "Total revenue guidance was lowered to $9.9-10.1B, from $11.0-11.2B and cash EPS guidance... More

Valeant Pharma (VRX) 1Q16 Was A Clean-Up Quarter - Guggenheim

Guggenheim analyst, Louise Chen, defended Valeant Pharmaceuticals (NYSE: VRX) as she continues to believe that VRX's long-term growth prospects are underappreciated. Upside to expectations could come from: 1) divestment of non-core products to pay down debt; 2) meeting or beating quarterly earnings in '16; and, 3)... More

Valeant (VRX) PT Cut to $38 at BMO Capital

BMO Capital analyst Alex Arfaei reiterated a Market Perform rating and cut his price target on Valeant Pharmaceuticals (NYSE: VRX) to $38.00 (from $44.00) after the company cut guidance. While the firm expected the cut, it was greater than they and the market expected.

Arfaei commented, "Although we expected Valeant to lower its guidance, the magnitude of the downward revision was greater than we and the market expected. This... More

Valeant (VRX) Product Commentary 'Concerning', Piper Jaffray Says; PT Set at $19

Piper Jaffray David Amsellem analyst reiterated an Underweight rating and reinstated a $19 price target on Valeant Pharmaceuticals (NYSE: VRX) following Q1 results.

Amsellem said he was not surprised to see a downward revision to 2016 guidance. What was more troubling in their view was... More

Valeant Pharma (VRX) EBITDA Guidance Just Above Maintenance Covenants - Evercore ISI's Raffat

Evercore ISI analyst Umer Raffat notes that Valeant Pharma (NYSE: VRX) EBITDA guidance was bit below buyside consensus and right around maintenance covenants. In addition, Xifaxan is underperforming.

Raffat notes that Valeant's updated 2016 adj EBITDA guidance was $4.8 - $4.95 billion, versus the buyside... More

Valeant Pharma (VRX) Misses Q1 EPS by 10c; Cuts FY16 Outlook

Valeant Pharma (NYSE: VRX) reported Q1 EPS of $1.27, $0.10 worse than the analyst estimate of $1.37. Revenue for the quarter came in at $2.37 billion versus the consensus estimate of $2.39 billion.

"The first quarter's results reflect, in part, the impact of significant disruption this organization has faced over the past nine months," said Joseph Papa, chairman and chief executive... More